Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Sarcoma 5Neoplasms 5Rhabdomyosarcoma 4Prostatic Neoplasms 4Osteosarcoma 3Breast Neoplasms 3Sarcoma, Synovial 2Sarcoma, Ewing 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Lung Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Retinoblastoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neuroblastoma 1Mesothelioma, Malignant 1Liver Neoplasms 1Liposarcoma 1

Interventions

Radiotherapy 11Cisplatin 10Paclitaxel 9pembrolizumab 7Fluorouracil 7Oxaliplatin 6Irinotecan 6tislelizumab 5Cetuximab 5Docetaxel 4Radiation 3Nivolumab 3Leucovorin 3Carboplatin 3Capecitabine 3Neoadjuvant Therapy 2Immunohistochemistry 2Biopsy 210-propargyl-10-deazaaminopterin 2tremelimumab 1sitravatinib 1sintilimab 1regorafenib 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1oblimersen 1durvalumab 1cixutumumab 1adavosertib 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Squamous Cell Carcinoma × cixutumumab × Clear all
NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡